Aarti Pharmalabs Ltd reports Q2 FY27 revenue of ₹610.45 crore, up 45.9% year on year, and net profit of ₹71.47 crore.
- Revenue rose 13.9% sequentially; net profit was down 6.1% sequentially. Operating margin was approximately 22.2% on an EBITDA-proxy basis.
- Results include a ₹2.04 crore exceptional provision related to a stamp-duty order; a further ₹57.46 crore was disclosed as a contingent liability. Auditors’ review conclusion was unmodified, with emphasis-of-matter paragraphs noting restated comparative figures.
- CFO Piyush Lakhani resigns effective October 30; Vibha Thakkar takes over as CFO from October 31, 2026.